Beam Therapeutics Inc. Operating Cash Flow
Beam Therapeutics Inc. (BEAM) reported Operating Cash Flow of -$194.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-04
- Beam Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$66.10M.
- Beam Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$128.51M.
- Beam Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$83.29M.
- Beam Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$81.48M.
- Beam Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$345.10M.
- Beam Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$347.25M.
- Beam Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$149.19M, a 762.29% decline from fiscal 2022.
- Beam Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2022 was $22.53M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$66.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$194.61M 10-Q · filed 2026-08-04 | -$277.90M derived: sum of 3 quarters · filed 2026-08-04 | -$359.38M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$128.51M 10-Q · filed 2026-05-07 | -$211.80M derived: sum of 2 quarters · filed 2026-05-07 | -$293.28M derived: sum of 3 quarters · filed 2026-05-07 | -$369.73M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$83.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$164.77M derived: sum of 2 quarters · filed 2026-02-24 | -$241.22M derived: sum of 3 quarters · filed 2026-08-04 | -$345.10M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$81.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$157.93M derived: sum of 2 quarters · filed 2026-08-04 | -$261.81M 10-Q · filed 2025-11-04 | -$338.18M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$76.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$180.33M 10-Q · filed 2026-08-04 | -$256.70M derived: sum of 3 quarters · filed 2026-08-04 | -$344.82M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$103.88M 10-Q · filed 2026-05-07 | -$180.25M derived: sum of 2 quarters · filed 2026-05-07 | -$268.37M derived: sum of 3 quarters · filed 2026-05-07 | -$351.38M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$76.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$164.49M derived: sum of 2 quarters · filed 2026-02-24 | -$247.50M derived: sum of 3 quarters · filed 2026-02-24 | -$347.25M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$88.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$171.13M derived: sum of 2 quarters · filed 2025-11-04 | -$270.88M 10-Q · filed 2025-11-04 | -$135.81M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$83.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$182.76M 10-Q · filed 2025-08-05 | -$47.68M derived: sum of 3 quarters · filed 2026-02-24 | -$137.47M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$99.75M 10-Q · filed 2025-05-06 | $35.33M derived: sum of 2 quarters · filed 2026-02-24 | -$54.46M derived: sum of 3 quarters · filed 2026-02-24 | -$139.13M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $135.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $45.29M derived: sum of 2 quarters · filed 2026-02-24 | -$39.38M derived: sum of 3 quarters · filed 2026-02-24 | -$149.19M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$89.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$174.45M derived: sum of 2 quarters · filed 2024-11-05 | -$284.27M 10-Q · filed 2024-11-05 | -$353.46M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$84.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$194.48M 10-Q · filed 2024-08-06 | -$263.68M derived: sum of 3 quarters · filed 2025-02-25 | -$338.17M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$109.81M 10-Q · filed 2024-05-07 | -$179.01M derived: sum of 2 quarters · filed 2025-02-25 | -$253.50M derived: sum of 3 quarters · filed 2025-02-25 | -$305.78M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$69.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$143.69M derived: sum of 2 quarters · filed 2025-02-25 | -$195.96M derived: sum of 3 quarters · filed 2025-02-25 | $22.53M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$74.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$126.77M derived: sum of 2 quarters · filed 2023-11-08 | $91.72M 10-Q · filed 2023-11-08 | $93.55M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$52.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $166.21M 10-Q · filed 2023-08-08 | $168.04M derived: sum of 3 quarters · filed 2024-02-27 | $171.05M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $218.49M 10-Q · filed 2023-05-10 | $220.32M derived: sum of 2 quarters · filed 2024-02-27 | $223.33M derived: sum of 3 quarters · filed 2024-02-27 | $190.80M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $4.84M derived: sum of 2 quarters · filed 2024-02-27 | -$27.69M derived: sum of 3 quarters · filed 2024-02-27 | -$66.27M 10-K · filed 2024-02-27 |
| 2021-09-30 | $3.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$29.52M derived: sum of 2 quarters · filed 2022-11-07 | -$68.10M 10-Q · filed 2022-11-07 | -$92.40M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$32.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$71.11M 10-Q · filed 2022-08-09 | -$95.40M derived: sum of 3 quarters · filed 2023-02-28 | -$116.62M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$38.58M 10-Q · filed 2022-05-09 | -$62.88M derived: sum of 2 quarters · filed 2023-02-28 | -$84.09M derived: sum of 3 quarters · filed 2023-02-28 | -$106.93M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$24.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$45.51M derived: sum of 2 quarters · filed 2023-02-28 | -$68.35M derived: sum of 3 quarters · filed 2023-02-28 | -$95.74M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$21.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$44.05M derived: sum of 2 quarters · filed 2021-11-08 | -$71.44M 10-Q · filed 2021-11-08 | -$89.24M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$22.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$50.23M 10-Q · filed 2021-08-10 | -$68.03M derived: sum of 3 quarters · filed 2022-02-28 | -$85.02M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$27.39M 10-Q · filed 2021-05-11 | -$45.19M derived: sum of 2 quarters · filed 2022-02-28 | -$62.19M derived: sum of 3 quarters · filed 2022-02-28 | -$73.54M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$17.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$34.79M derived: sum of 2 quarters · filed 2022-02-28 | -$46.15M derived: sum of 3 quarters · filed 2022-02-28 | -$72.00M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$16.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$28.35M derived: sum of 2 quarters · filed 2020-11-10 | -$54.20M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$11.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | -$37.21M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | -$25.86M 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |